ArticleFrontiers in oncology2026
A decade of esophageal cancer in Kazakhstan: what the national cancer registry reveals (2014-2023).
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Esophageal cancer (EC) is a major yet understudied public health burden in Central Asia. Kazakhstan has one of the highest EC rates in the region, but national epidemiological trends and survival outcomes remain poorly reported. Epidemiological trends among younger adults are largely unexplored, despite growing concern about early-onset gastrointestinal cancers. This study assessed recent patterns in EC incidence, mortality, disease burden, and survival across Kazakhstan from 2014 to 2023. Methods: We conducted a retrospective, population-based cohort study including all EC patients registered in the National Cancer Registry between Jan 1, 2014, and Dec 31, 2023. Demographic, clinical, and survival data were extracted from registry-linked records. Early-onset EC was defined as diagnosis before age 45. Age-standardized incidence, mortality, and prevalence rates per 100,000 were calculated using the WHO World Standard Population. DALYs were estimated following GBD 2023 methodology. Survival was assessed using Kaplan-Meier methods; predictors were analyzed with Cox regression. Results: The cohort included 24,778 patients. The age-standardized incidence rate was 13.9 per 100,000 (95% CI 12.6-15.1). Mortality rose from 4.4 per 100,000 in 2014 to 10.6 per 100,000 in 2023, peaking at 12.3 per 100,000 in 2018. DALYs increased from 3,383 (95% UI 2,970-3,800) to 8,300 (95% UI 6,691-9,269) per 100,000, 95% attributable to YLL. In early-onset cases, DALYs per 100,000 tripled over ten years. Three-year survival declined from 62.9% (95% CI 59.2-66.6) at Stage I to 12.9% (95% CI 10.8-15.0) at Stage IV. Male sex (aHR 1.11), advanced stage (aHR 7.10), and alcohol disorders (aHR 1.15) were associated with poorer survival. Kyzylorda and Karaganda regions had the highest burden. Interpretation: Despite stable incidence, EC mortality in Kazakhstan has tripled over the past decade, reflecting late-stage diagnosis, limited treatment access, and persistent modifiable risk factors such as alcohol and tobacco use. These findings highlight a critical public health gap and underscore the need for early detection programs and strengthened oncology infrastructure to reduce premature mortality in Kazakhstan and neighboring countries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.